HilleVax Inc (HLVX): רווח למניה בשנים עשר החודשים האחרונים

HilleVax, Inc. (HLVX) management is currently adjusting its R&D plan following previous difficulties. The trailing twelve-month earnings per share on the GURU.Markets chart shows a sharp impulse, with a value of -1.44. This reinforces the potential of the HIL-214 norovirus vaccine. The absence of competitors in this niche allows the company to pursue a monopoly and establish pricing power for the drug.
פילוחים אנליטיים של חברת HilleVax Corp (HLVX)

For HilleVax, Inc., which develops norovirus vaccines, this indicator serves as a measure of R&D monetization efficiency. The metric calculates total annual net income divided by the total number of shares. By analyzing the net income per share TTM snapshot on the GURU.Markets platform, an investor can determine the actual per-share income, which allows them to eliminate the impact of share issuance. The indicator's trend reflects the company's sensitivity to the cost of borrowed capital.